Literature DB >> 11118354

Building a better vector: the manipulation of AAV virions.

J E Rabinowitz1, R J Samulski.   

Abstract

Mesh：

Year:  2000        PMID： 11118354     DOI： 10.1006/viro.2000.0707

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


× No keyword cloud information.
  20 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.

Authors:  Joseph E Rabinowitz; Dawn E Bowles; Susan M Faust; Julie G Ledford; Scott E Cunningham; R Jude Samulski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy.

Authors:  Hiromu Ito; Mette Koefoed; Prarop Tiyapatanaputi; Kirill Gromov; J Jeffrey Goater; Jonathan Carmouche; Xinping Zhang; Paul T Rubery; Joseph Rabinowitz; R Jude Samulski; Takashi Nakamura; Kjeld Soballe; Regis J O'Keefe; Brendan F Boyce; Edward M Schwarz
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

Review 4.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

5.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Authors:  Carmen S Peden; Fredric P Manfredsson; Sharon K Reimsnider; Amy E Poirier; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

Review 6.  Adeno-associated virus-mediated microRNA delivery and therapeutics.

Authors:  Jun Xie; Daniel Robert Burt; Guangping Gao
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

7.  Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production.

Authors:  Dawn E Bowles; Joseph E Rabinowitz; R Jude Samulski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.

Authors:  Mei Hong Tan; Alexander J Smith; Basil Pawlyk; Xiaoyun Xu; Xiaoqing Liu; James B Bainbridge; Mark Basche; Jenny McIntosh; Hoai Viet Tran; Amit Nathwani; Tiansen Li; Robin R Ali
Journal:  Hum Mol Genet       Date:  2009-03-19       Impact factor: 6.150

9.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016

10.  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.

Authors:  Declan Madsen; Emma R Cantwell; Timothy O'Brien; Patricia A Johnson; Bernard P Mahon
Journal:  J Gen Virol       Date:  2009-07-29       Impact factor: 3.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.